ArticleCancer research2002
Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.
Article in Cancer research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Boosting the Immune Response-Combining Local and Immune Therapy for Prostate Cancer Treatment.Cells · 2022Review
- Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.Pharmaceutics · 2022Review
- Ubi Maior Minor Cessat.Critical reviews in immunology · 2020Article
- Challenges and future perspectives of T cell immunotherapy in cancer.Immunology letters · 2015Review
- An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.PloS one · 2015Article
- GILT: Shaping the MHC Class II-Restricted Peptidome and CD4(+) T Cell-Mediated Immunity.Frontiers in immunology · 2013Review
- GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1.The Journal of investigative dermatology · 2012Article
- Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductase.Antioxidants & redox signaling · 2011Review
- Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.The Journal of clinical investigation · 2010Article
- GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Update on vaccine development for renal cell cancer.Open access journal of urology · 2010Review
- High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2009Article
- Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Article
- Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53.Cancer immunology, immunotherapy : CII · 2005Article
- Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.Vaccine · 2004Article
- Identification of tumor antigens and T-cell epitopes, and its clinical application.Cancer immunology, immunotherapy : CII · 2004Review
- Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.The Journal of experimental medicine · 2003Article
- Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.Journal of immunology (Baltimore, Md. : 1950) · 2003Article
- Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.Nature medicine · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
CD4(+) T cells can recognize "self" tumor antigens, but the impact of tumor cell expression of self-antigens on CD4(+) T-cell function in humans is unknown. Here, we identify a new epitope (ISPNSVFSQWRVVCDSLEDYD) derived from tyrosinase-related protein-1 (TRP-1) using a predictive algorithm and mice transgenic for a chimeric HLA-DRB1*0401 molecule. We then compared the functions of TRP-1-epitope-specific, CD4(+) T-cell responses in normal healthy individuals to those found in patients with metastatic malignant melanoma. Surprisingly, we found that tumor-bearing patients had significantly higher levels of TRP-1-specific, CD4(+) T-cell function than healthy volunteers as measured ex vivo. Thus, the net effect of "self" antigen expression by tumor cells was the enhancement of tumor antigen-specific CD4(+) T-cell function, rather than immunosuppression. These findings indicate that antigens expressed by malignant melanoma cells can partially activate CD4(+) T lymphocytes.
Indexed as
Identifiers
12234976PMC2248802W2169308798What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.